WIRE โ€” SAN DIEGO, US Media OutReach Newswire 9 July 2026 Sapu Nano (US) LLC, a clinical-stage biotechnology company developing the proprietary Deciparticleโ„ข nanomedicine platform, today announced that the independent Safety Review Committee (SRC) has completed its review of the initial safety cohort in the Companys ongoing SP-03-B101 Phase 1b clinical trial evaluating Sapu003, The post Sapu Nano Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway appeared first on iHarare News.

"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."

This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.